ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0102

Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Abstract Number: 0103

Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Abstract Number: 0104

Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
Abstract Number: 0105

Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Abstract Number: 0106

COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Abstract Number: 0107

Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
Abstract Number: 0108

Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 0109

COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 0110

Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Abstract Number: 0111

Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Abstract Number: 0112

A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics
Abstract Number: 0113

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Abstract Number: 0114

The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Abstract Number: 0115

Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020
Abstract Number: 0116

COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].